SRCM
OBIO icon

Sage Rock Capital Management’s Orchestra BioMed OBIO Stock Holding History

Sage Rock Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-18,285
Closed -$201K – 137
2020
Q3 		$201K Buy
+18,285
New +$205K 0.04% 100

Other funds holding OBIO

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Sage Rock Capital Management's OBIO Position: Q4 2020 in Review

Sage Rock Capital Management sold out of Orchestra BioMed (OBIO) in Q4 2020, closing a stake of 18,285 shares — an estimated $201K sold.

Sage Rock Capital Management first reported a position in OBIO in Q3 2020 and held it in 1 quarter. The position peaked at $201K in Q3 2020. 46 funds tracked by Wall St. Rank hold OBIO as of Q4 2020.

  • Sage Rock Capital Management reported no remaining Orchestra BioMed position as of Q4 2020 after selling out during the quarter.
  • Sage Rock Capital Management sold 18,285 Orchestra BioMed shares in Q4 2020, an estimated $201K.
  • Sage Rock Capital Management first reported a position in Orchestra BioMed in Q3 2020 and held it in 1 quarter.
  • Sage Rock Capital Management's Orchestra BioMed position peaked at $201K in Q3 2020.
  • 46 funds tracked by Wall St. Rank held Orchestra BioMed as of Q4 2020.

Based on Sage Rock Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.